← Back to Screener
INVO Fertility, Inc. Common Stock (IVF)
Price$1.47
Value ScoreA
Growth ScoreB
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-100.77%
Price vs S&P 500 (4W)-6.02%
VGM Score61.90
Market Capitalization$3.04M
All Metrics
Book Value / Share (Quarterly)$43.13
P/TBV (Annual)1.07x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)16.23%
Cash Flow / Share (Quarterly)$-57.28
Price vs S&P 500 (YTD)-61.07%
Gross Margin (TTM)39.17%
Net Profit Margin (TTM)-417.01%
EPS (TTM)$-2092.32
10-Day Avg Trading Volume1.30M
EPS Excl Extra (TTM)$-2092.32
Revenue Growth (5Y)34.57%
EPS (Annual)$-43313.52
ROI (Annual)-32.87%
Gross Margin (Annual)44.00%
Net Profit Margin (5Y Avg)-539.21%
Cash / Share (Quarterly)$2.62
Revenue Growth QoQ (YoY)22.60%
ROA (Last FY)-19.58%
Revenue Growth TTM (YoY)11.50%
EBITD / Share (TTM)$-426.99
ROE (5Y Avg)-241.27%
Operating Margin (TTM)-382.53%
Cash Flow / Share (Annual)$-12146.54
P/B Ratio0.52x
P/B Ratio (Quarterly)0.57x
Net Income / Employee (Annual)$-324,900
EV / Revenue (TTM)0.67x
Net Interest Coverage (TTM)-7.71x
ROA (TTM)-99.55%
EPS Incl Extra (Annual)$-43313.52
Current Ratio (Annual)0.07x
Quick Ratio (Quarterly)0.07x
3-Month Avg Trading Volume0.40M
52-Week Price Return-99.08%
Revenue / Employee (TTM)$248,000
Tangible BV / Share (Quarterly)$32.58
P/S Ratio (Annual)0.46x
Asset Turnover (Annual)0.14x
52-Week High$210.00
Operating Margin (5Y Avg)-460.75%
EPS Excl Extra (Annual)$-43313.52
CapEx CAGR (5Y)10.80%
26-Week Price Return-84.84%
Quick Ratio (Annual)0.05x
13-Week Price Return-60.75%
Total Debt / Equity (Annual)0.37x
Current Ratio (Quarterly)0.12x
Enterprise Value$4.66M
Revenue / Share Growth (5Y)450.24%
Asset Turnover (TTM)0.24x
Revenue / Employee (Annual)$233,300
Inventory Turnover (Annual)15.11x
Pretax Margin (Annual)-139.60%
Cash / Share (Annual)$2851.54
3-Month Return Std Dev90.48%
Gross Margin (5Y Avg)65.54%
Net Income / Employee (TTM)$-1,034,200
ROE (Last FY)-45.02%
Net Interest Coverage (Annual)-29.48x
EPS Basic Excl Extra (Annual)$-43313.52
Receivables Turnover (TTM)26.14x
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$-2092.32
Receivables Turnover (Annual)41.42x
ROI (TTM)-204.20%
P/S Ratio (TTM)0.44x
Pretax Margin (5Y Avg)-539.09%
Revenue / Share (Annual)$31104.76
Tangible BV / Share (Annual)$8079.00
Price vs S&P 500 (52W)-127.28%
Year-to-Date Return-50.13%
5-Day Price Return14.63%
EPS Normalized (Annual)$-43313.52
ROA (5Y Avg)-93.68%
Net Profit Margin (Annual)-139.25%
Month-to-Date Return0.00%
EBITD / Share (Annual)$-34056.38
Operating Margin (Annual)-123.57%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-99.68%
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-2092.32
P/TBV (Quarterly)0.75x
P/B Ratio (Annual)0.11x
Inventory Turnover (TTM)19.50x
Pretax Margin (TTM)-387.89%
Book Value / Share (Annual)$77709.50
Price vs S&P 500 (13W)-70.50%
Beta2.37x
P/FCF (Annual)2.41x
Revenue / Share (TTM)$80.56
ROE (TTM)-321.75%
52-Week Low$1.38
vGradeA
gGradeB
mGradeF
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IVFINVO Fertility, Inc. Common Stock | A | B | F | $1.47 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
INVO Fertility Inc. is a healthcare company focused on expanding access to assisted reproductive technology through its proprietary INVOcell medical device, which enables fertilization and early embryo development to occur within the patient's body. The company operates through three revenue-generating segments: clinical services (including its WFI and Atlanta-based clinics), INVOcell device manufacturing and sales, and therapeutics through its acquired subsidiary NTI. This diversified model combines direct patient care with medical device commercialization to address the growing fertility treatment market.